Literature DB >> 21316759

Some novel features of IDH1-mutated acute myeloid leukemia revealed in Chinese patients.

Yiqun Zhang1, Hui Wei, Min Wang, Lei Huai, Yingchang Mi, Yizhi Zhang, Dong Lin, Bingcheng Liu, Wei Li, Chunlin Zhou, Qing Rao, Jianxiang Wang.   

Abstract

Mutations of isocitrate dehydrogenase 1 (IDH1) have recently been reported in acute myeloid leukemia (AML). However, the characteristics of IDH1-mutated AML are still not known clearly. We analyzed 416 Chinese AML patients and found 28 patients (6.7%) carried this mutation. One homozygous IDH1 mutant in AML was found. The IDH1 mutations were associated with NPM1 mutations (P=0.043) and could coexist with recurrent transcription factor aberrations including AML1-ETO (6/50), PML-RARα (3/77) and CBFβ-MYH11 (1/15). For AML with AML1-ETO fusion gene, IDH1(mut) patients may have worse disease-free survival (DFS) than IDH1(wild-type) patients.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21316759     DOI: 10.1016/j.leukres.2011.01.019

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  8 in total

1.  Prevalence and Prognostic Value of IDH1 R132 Mutation in Newly Diagnosed AML Egyptian Patients with Normal Karyotype.

Authors:  Dalia Salem; Sherin Abd El-Aziz; Nadia El-Menshawy; Tarek Abouzeid; Mohamed Ebrahim
Journal:  Indian J Hematol Blood Transfus       Date:  2016-02-18       Impact factor: 0.900

2.  Mutation analysis of isocitrate dehydrogenase in acute lymphoblastic leukemia.

Authors:  Yiqun Zhang; Hui Wei; Kejing Tang; Dong Lin; Cuiping Zhang; Yingchang Mi; Lin Wang; Cuicui Wang; Min Wang; Jianxiang Wang
Journal:  Genet Test Mol Biomarkers       Date:  2012-07-18

3.  Prognostic significance of IDH1 mutations in acute myeloid leukemia: a meta-analysis.

Authors:  Jian-Hua Feng; Xiao-Ping Guo; Yuan-Yuan Chen; Zhu-Jun Wang; Yu-Ping Cheng; Yong-Min Tang
Journal:  Am J Blood Res       Date:  2012-11-25

4.  Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.

Authors:  Sadudee Chotirat; Wanna Thongnoppakhun; Orathai Promsuwicha; Chetsada Boonthimat; Chirayu U Auewarakul
Journal:  J Hematol Oncol       Date:  2012-03-07       Impact factor: 23.168

5.  IDH1/IDH2 but not TP53 mutations predict prognosis in Bulgarian glioblastoma patients.

Authors:  Gergana Stancheva; Teodora Goranova; Maria Laleva; Margarita Kamenova; Atanaska Mitkova; Nikolay Velinov; George Poptodorov; Vanio Mitev; Radka Kaneva; Nikolay Gabrovsky
Journal:  Biomed Res Int       Date:  2014-04-24       Impact factor: 3.246

Review 6.  Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic Strategies.

Authors:  Hanumantha Rao Madala; Surendra R Punganuru; Viswanath Arutla; Subhasis Misra; T J Thomas; Kalkunte S Srivenugopal
Journal:  Cancers (Basel)       Date:  2018-02-11       Impact factor: 6.639

7.  Promoter Methylation Analysis of IDH Genes in Human Gliomas.

Authors:  Simon Flanagan; Maggie Lee; Cheryl C Y Li; Catherine M Suter; Michael E Buckland
Journal:  Front Oncol       Date:  2012-12-19       Impact factor: 6.244

8.  The Frequency and clinical significance of IDH1 mutations in Chinese acute myeloid leukemia patients.

Authors:  Lixun Guan; Li Gao; Lili Wang; Meng Li; Yue Yin; Li Yu; Chunji Gao
Journal:  PLoS One       Date:  2013-12-20       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.